BioSim, a Seattle-based pharmaceutical company, focuses on building a portfolio around generic drugs for the orphan disease markets.

BioSim, started in early 2012, consists of a team of highly capable individuals with decades of pharmaceutical industry experience all working together to bring products to market that help lower the escalating cost of healthcare.

A technology driven company, BioSim looks to create, over the next few years, a significant product pipeline in the US, while continuing to explore partnerships to enhance our research and commercial opportunities.